Clinical Trials in New York

Showing 3121-3140 of 22,668 trials

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels

NCT05241262

N-Acetylcysteine (NAC), an anti-oxidant, will be studied to investigate the effects on brain glutathione levels, cognitive skills, motor skills, and quality of life. A group of 18 participants will take either 1800, 3600 or 5400 mg per day of N-acetylcysteine (NAC) for 3 months in this dose escalation study. The investigators want to determine first if the 3600 mg dose per day is safe and might provide some efficacy. If the 3600 mg dose is safe, then additional participants will be treated with 5400 mg per day of NAC, for up to a total of 18 participants. If the 3600 mg per day dose is unsafe, then participants will be treated with the 1800 mg per day dose. Data from this pilot study will be used to determine the most safe and effective dose of NAC for a future clinical trial.

Mitochondrial Disease

Michio Hirano, MD18 participantsStarted Jul 2023

New York, New York, United States

Active Not RecruitingPhase 2/3< 1 mile

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

NCT05217628

Trigeminal neuralgia (TN), also called "tic douloureux", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice. This study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN.

Trigeminal Neuralgia

Noema Pharma AG166 participantsStarted Jan 2022

La Jolla, California, United States • Miami, Florida, United States • Tampa, Florida, United States +31 more locations

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

Find Trials by Condition in New York

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Veteran Peer Navigators to Promote Shared Decision Making for PSA Screening

Measuring Physical Activity With ActivPal

Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease

Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository

Diffusion MRI for Head and Neck Cancer

Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

Mind-Body Skills Group for Graduate Students

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments